Metronidazole-based dermatological foam and emulsions for the production thereof
AssigneeGalderma S.A.
InventorsDov TAMARKIN, Doron Friedman
Life of this patent
Estimating the term…
Abstract
Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain: (a) 72% to 76% of water; (b) 0.1% to 5% of a gelling agent for the aqueous phase of the emulsion; (c) 0.75% to 2% of metronidazole; (d) 5% to 10% of mineral oil; (e) 0.5% to 10% of a surfactant; (f) 0.5% to 5% of a fatty acid; (g) 0% to 4% of a metronidazole absorption promoter (c); and (h) 0.1% to 5% of a preservative selected from the group consisting of methylparaben, propylparaben, phenoxyethanol and mixtures thereof.
Claims23
A stable, metronidazole-based oil-in-water emulsion expandable into a topically applicable foam having a firm, creamy and light consistency, said foam also having improved release-penetration capacity, diminished inhibition of skin breathing and useful for the treatment of dermatological skin conditions/afflictions, comprising (a) water, (b) a gelling agent for the aqueous phase thereof, (c) a dermatologically effective amount of metronidazole, (d) mineral oil, (e) a surfactant, (f) a fatty acid, (g) a preservative and, optionally, (h) a metronidazole absorption promoter.
A stable metronidazole-based oil-in-water emulsion expandable into a topically applicable foam useful for the treatment of dermatological conditions/afflictions, comprising, by mass relative to the total mass of the emulsion:
- (a) 70% to 81% of water;
- (b) 0.1% to 5% of a gelling agent for the aqueous phase of the emulsion;
- (c) 0.75% to 2% of metronidazole;
- (d) 4% to 10% of mineral oil;
- (e) 0.5% to 10% of a surfactant;
- (f) 0.5% to 5% of a fatty acid;
- (g) 0.1% to 5% of a preservative;
- and
- (h) 0% to 5% of a metronidazole absorption promoter.
Dependencies are inferred from the claim text.